Risk of second primary malignancies in older long-term survivors of breast, prostate, colon, and rectal cancer

Clicks: 18
ID: 332252
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #233 of 407 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 407 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Cancer survivors face an increased risk of second primary malignancies (SPMs). Understanding SPM incidence and risk factors is crucial for long-term survivorship care. Methods This was a SEER-Medicare retrospective cohort study of breast, prostate, colon, or rectal cancer survivors diagnosed between 2003-2011 at age 66+ years who survived ≥5 years post-diagnosis. The primary outcome was a ‘late’ SPM, defined as invasive cancer occurring ≥5 years after initial diagnosis. Restricted mean survival time (RMST) regression was used to assess demographic, clinical, and treatment related factors associated with late SPMs. SPMs were categorized as hematologic, screen-detectable (breast, prostate, lung, colon, or rectal), or non-screen detectable solid tumors. Results Of 90,261 long-term survivors, 11.2% (10,116) developed at least one late SPM. The cumulative incidence of late SPMs over 8 years was highest in prostate cancer survivors. Non-screen detectable cancers composed the largest proportion (47.8%) of 10,220 total late SPMs. The most common late SPM site was lung in colon (14.9%), and rectal (16.1%) cancer survivors, urinary bladder in prostate (17.0%), and new-primary breast cancers in breast cancer survivors (36.5%). In RMST regression, significant associations with demographic, index cancer, treatment, and clinical characteristics and late SPMs ranged from 3.6 months shorter to 4.4 months longer time without late SPM during the 8 years assessed. Conclusions Between 10-14% of older long-term cancer survivors developed a late SPM during 5-13 years after index cancer diagnosis. Over 40% of late SPMs were screen-detectable, highlighting the need for surveillance strategies beyond 5 years from index cancer diagnosis.
Reference Key
openalex_W7221690184 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tendai Kwaramba, Sarah Westvold, Jessica B. Long, Terry Hyslop, A. Silber, Faiza Yasin, Rebecca Forman, Melissa Taylor, Shi-Yi Wang, Michael Leapman, Ira Lewis Leeds, Michael Cecchini, Lisa P. Spees, Stephanie B. Wheeler, Cary Philip Gross, Kevin Oeffinger, Michaela Ann Dinan
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag383
URL
https://doi.org/10.1093/jnci/djag383
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.